A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.
The study aim was to assess the inductive properties of artemisinin antimalarials using mephenytoin as a probe for CYP2B6 and CYP2C19 enzymatic activity. The population pharmacokinetics of S-mephenytoin and its metabolites S-nirvanol and S-4'-hydroxymephenytoin, including enzyme turn-over models for induction, were described by nonlinear mixed effects modeling. Rich data (8-16 samples/occasion/subject) were collected from 14 healthy volunteers who received mephenytoin before and during ten days of artemisinin administration. Sparse data (3 samples/occasion/subject) were collected from 74 healthy volunteers who received mephenytoin before, during and after five days administration of artemisinin, dihydroartemisinin, arteether, artemether or artesunate. The production rate of CYP2B6 was increased 79.7% by artemisinin, 61.5% by arteether, 76.1% by artemether, 19.9% by dihydroartemisinin and 16.9% by artesunate. The production rate of CYP2C19 increased 51.2% by artemisinin, 14.8% by arteether and 24.9% by artemether. In conclusion, all studied artemisinin derivatives induced CYP2B6. CYP2C19 induction by arteether and artemether as well as CYP2B6 and CYP2C19 induction by artemisinin was confirmed. The inductive capacity is different among the artemisinin drugs, which is of importance when selecting drugs to be used in antimalarial combination therapy such that the potential for drug-drug interactions is minimized.
Elsherbiny
Doaa A
DA
Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, P.O. Box 591, BMC, Uppsala, 751 24, Sweden. Doaa.Elsherbiny@farmbio.uu.se
Asimus
Sara A
SA
Karlsson
Mats O
MO
Ashton
Michael
M
Simonsson
Ulrika S H
US
D000328:Adult; D000927:Anticonvulsants / Q000493:pharmacokinetics; D000962:Antimalarials / Q000494:pharmacology*; D000077549:Artemether; D037621:Artemisinins / Q000494:pharmacology*; D001189:Aryl Hydrocarbon Hydroxylases / Q000096:biosynthesis* / Q000235:genetics; D001711:Biotransformation; D065702:Cytochrome P-450 CYP2B6; D065731:Cytochrome P-450 CYP2C19; D004338:Drug Combinations; D004790:Enzyme Induction / Q000187:drug effects*; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008617:Mephenytoin / Q000493:pharmacokinetics; D015233:Models, Statistical; D010089:Oxidoreductases, N-Demethylating / Q000096:biosynthesis* / Q000235:genetics; D010641:Phenotype
D000927:Anticonvulsants; D000962:Antimalarials; D037621:Artemisinins; D004338:Drug Combinations; C031327:artemisinin; D000077549:Artemether; D001189:Aryl Hydrocarbon Hydroxylases; C585599:CYP2B6 protein, human; C045793:CYP2C19 protein, human; D065702:Cytochrome P-450 CYP2B6; D065731:Cytochrome P-450 CYP2C19; D010089:Oxidoreductases, N-Demethylating; D008617:Mephenytoin; C055141:artemotil